Core Insights - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for aggressive cancers, utilizing AMP technology to enhance immune responses against tumors [4][7]. Company Overview - Elicio Therapeutics, Inc. (Nasdaq: ELTX) is advancing a pipeline of novel immunotherapies aimed at treating aggressive cancers by leveraging the immune system's natural capabilities [4]. - The company’s AMP technology allows for direct delivery of therapeutic payloads to lymph nodes, optimizing the immune response to cancer [4]. Product Pipeline - The R&D pipeline includes ELI-002, targeting mKRAS-driven cancers, and ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively [4]. - ELI-002 is a novel investigational cancer vaccine designed to target mutations in the mKRAS gene, a common driver in many cancers [6][11]. Clinical Trials - The AMPLIFY-7P study is currently evaluating the 7-peptide formulation of ELI-002 in patients with mKRAS-driven solid tumors, with preliminary data showing promising results in disease-free survival (DFS) [6][7]. - As of the May 24, 2024 data cutoff, the median DFS has not yet been reached for patients receiving the 4.9mg AMP-peptide dose, while patients with a strong T cell response showed no progression events [8]. Data Highlights - In the AMPLIFY-7P study, patients receiving the 4.9mg dose have not reached the median DFS endpoint, contrasting with a median DFS of 12.6 weeks for those receiving a lower dose [8]. - Patients with reduced tumor biomarker levels experienced no progression events, indicating a correlation between T cell response and tumor reduction [8].
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P